본문 바로가기
KERD
논문KCI 등재

산소로 유도된 망막증 모델에서 트리암시놀론이 망막 혈관 관련 인자에 미치는 영향

Effect of Triamcinolone on Retinal Vessel-Related Factors in Oxygen-Induced Retinopathy Rats

정인영|서성욱|유지명|박종문|유웅선
대한안과학회 (The Korean Ophthalmological Society)|2012.12|대한안과학회지 (Journal of The Korean Ophthalmological Society)|제53권 제12호|pp. 1864-1869

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Vascular endothelial growth factorTriamcinolone acetonideHypoxia inducible factorOxygen-induced retinopathy (OIR)
주제분류안과학

초록

목적: 트리암시놀론 아세토나이드(TA)의 Oxygen-induced retinopathy (OIR) 쥐 모델에서 혈관 관련 인자 및 혈관 누출에 대한 효과를알아보고자 한다. 대상과 방법: Sprague-Dawley계 흰쥐를 생후 2일부터 14일까지 고농도 산소에 노출한 후 생후 15일부터 30일까지 정상산소에 노출시켜 대조군과 비교하였다. TA (4 mg/kg) 2 μl를 생후 16일에 유리체내로 주입하였다. 망막 혈관 누출 현상은 Evans blue method를이용하였고 RT-PCR을 이용하여 혈관관련인자들의 mRNA 변화를 보았다. 결과: OIR 모델 흰쥐는 상대적 저산소로 인한 혈관누출이 나타났으며 TA을 주입하였을 때 혈관 투과성이 대조군에 비해 현저히 감소하였다. OIR 모델에서 HIF-1α, VEGF, SDF-1, ICAM-1의 mRNA 증가를 보였으며 TA 처리시 감소하였다. 또한 Occludin mRNA는 감소를보였으며 TA 처리시 증가하였다. 결론: OIR 모델에서 TA처리시 망막혈관누출의 감소를 보이며 이는 TA가 혈관누출억제에 작용하는 것으로 생각한다. 또한 허혈망막증에 증가하며 트리암시놀론 처리시 감소되는 것으로 이미 보고된 HIF-1α 및 VEGF 뿐만 아니라, SDF-1, ICAM-1, Occludin과 같은망막혈관 관련 인자에도 트리암시놀론이 작용하여 망막혈관파괴에 방지 효과가 있을 것으로 생각하며 추후 각 인자들의 단백질 변화를 통한 확인이 필요할 것이다.

Abstract

Purpose: The present study investigated the effects of triamcinolone acetonide (TA) on retinal vessel-related factors and retinal vascular leakage in the retina of oxygen-induced retinopathy (OIR) rats. Methods: Sprague-Dawley rats used for OIR were exposed to hyperoxia from postnatal day 2 to day 14, then returned to normoxia from day 15 to day 30 and compared with control rats. On postnatal day 16, 2 μl of TA (4 mg/kg) was injected into the vitreous of the right eye in control and OIR rats. The Evans blue method was used for evaluating vascular leakage and RT-PCR was performed for confirmation of mRNA expression. Results: In OIR rats exposed to hyperoxia, retinal vascular permeability increased when returned to normoxia. After intravitreal injection of TA, vascular permeability was decreased in OIR rats, but no changes were found in control rats. In OIR rats, mRNAs of HIF-1α, VEGF, SDF-1 and ICAM-1 were more expressed and down-regulated after intravitreal injection of TA. Occludin mRNA level was decreased in the hypoxic condition and up-regulated after TA treatment. Conclusions: The present study suggests the ability of TA to inhibit retinal vascular leakage in OIR rats and a possibility that TA controls expression of the HIF-1, VEGF, SDF-1, ICAM-1 and Occludin, which may protect retinal vascular destruction from hypoxic conditions; further studies are necessary to confirm changes in protein levels.

참고문헌 (48)

  1. Hebbandi SB, "Ocular sequelae in extremely premature infants at 5 years of age", J Paediatr Child Health, 33, pp.339~342 (1997)
  2. Moore A., "Retinopathy of prematurity", pp.365~375 (1990), Blackwell Scientific
  3. Noma H, "Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin", Arch Ophthalmol, 120, pp.1075~1080 (2002)
  4. Raisler BJ, "Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization", Proc Natl Acad Sci U S A, 99, pp.8909~8914 (2002)
  5. Adamis AP, "Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy", Am J Ophthalmol, 118, pp.445~450 (1994)
  6. Aiello LP, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders", N Engl J Med, 331, pp.1480~1487 (1994)
  7. Malecaze F, "Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy", Arch Ophthalmol, 112, pp.1476~1482 (1994)
  8. Brafman A, "Inhibition of oxygen-induced retinopathy in RTP801-deficient mice", Invest Ophthalmol Vis Sci, 45, pp.3796~3805 (2004)
  9. Treins C, "Regulation of vascular endothelial growth factor expression by advanced glycation end products", J Biol Chem, 276, pp.43836~43841 (2001)
  10. Poulaki V, "Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia- inducible factor-1alpha and VEGF", J Clin Invest, 109, pp.805~815 (2002)
  11. Grimm C, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration", Nat Med, 8, pp.718~724 (2002)
  12. Grunewald M, "VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells", Cell, 124, pp.175~189 (2006)
  13. Lima e Silva R, "The SDF-1", CXCR4 ligand, FASEB J, pp.2007, 21[DOI]
  14. Antonetti DA, "Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group", Diabetes, 47, pp.1953~1959 (1998)
  15. McAllister IL, "Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion", Am J Ophthalmol, 147, pp.838~ (2009)
  16. Kim I, "Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells", J Biol Chem, 276, pp.7614~7620 (2001)
  17. Joussen AM, "Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo", Am J Pathol, 160, pp.501~509 (2002)
  18. Clauss M, "Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration", J Exp Med, 172, pp.1535~1545 (1990)
  19. Barleon B, "Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1", Blood, 87, pp.3336~3343 (1996)
  20. Sunderkötter C, "Macrophages and angiogenesis", J Leukoc Biol, 55, pp.410~422 (1994)
  21. Ferrara N., "Vascular endothelial growth factor: basic science and clinical progress", Endocr Rev, 25, pp.581~611 (2004)
  22. Sakurai E, "Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization", Invest Ophthalmol Vis Sci, 44, pp.2743~2749 (2003)
  23. Tatar O, "Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization", Arch Ophthalmol, 127, pp.275~281 (2009)
  24. Kim YH, "Triamcinolone suppresses retinal interruption of proinflammatory vascular pathology via a potent signal-regulated activation of VEGF during a relative hypoxia", NEUROBIOLOGY OF DISEASE, 26(3), pp.569~576 (2007), ACADEMIC PRESS INC ELSEVIER SCIENCE
  25. Antcliff RJ, "Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study", Ophthalmology, 108, pp.765~772 (2001)
  26. Young S, "Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis", Clin Experiment Ophthalmol, 29, pp.2~6 (2001)
  27. Jonas JB, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema", Am J Ophthalmol, 132, pp.425~427 (2001)
  28. Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy", Br J Ophthalmol, 84, pp.1064~1067 (2000)
  29. Danis RP, "Intravitreal triamcinolone acetonide in exudative age-related macular degeneration", Retina, 20, pp.244~250 (2000)
  30. Challa JK, "Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up", Aust N Z J Ophthalmol, 26, pp.277~281 (1998)
  31. Xu Q, "Sensitive blood–retinal barrier breakdown quantitation using Evans blue. Invest", Ophthalmol Vis Sci, 42, pp.789~794 (2001)
  32. Kim YS, "Retinal expression of clusterin in the streptozotocin-induced diabetic rat", Brain Res, 976, pp.53~59 (2003)
  33. Shih SC, "Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity", J Clin Invest, 112, pp.50~57 (2003)
  34. Leske DA, "The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP", Mol Vis, 10, pp.43~50 (2004)
  35. Zhang SX, "Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen- induced retinopathy", Am J Pathol, 166, pp.313~321 (2005)
  36. Gao G, "Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage", Diabetologia, 46, pp.689~698 (2003)
  37. Ozaki H, "Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates", Exp Eye Res, 64, pp.505~517 (1997)
  38. Saishin Y, "VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier", J Cell Physiol, 195, pp.241~248 (2003)
  39. Nambu H, "Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier", Gene Ther, 11, pp.865~873 (2004)
  40. Houle JM, "Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin", Retina, 22, pp.691~697 (2002)
  41. Brooks HL Jr, "Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone", Arch Ophthalmol, 122, pp.1801~1807 (2004)
  42. Danis RP, "Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide", Ophthalmology, 103, pp.2099~2104 (1996)
  43. Jonas JB, "Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases", Ophthalmologe, 101, pp.113~120 (2004)
  44. Lai DR, "Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases", J Oral Pathol Med, 24, pp.402~406 (1995)
  45. Matsuda S, "Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress", Invest Ophthalmol Vis Sci, 46, pp.1062~1068 (2005)
  46. Lipworth BJ., "Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis", Arch Intern Med, 159, pp.941~955 (1999)
  47. Takahashi K, "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment", FASEB J, 17, pp.896~898 (2003)
  48. Sima J, "The effect of angiostatin on vascular leakage and VEGF expression in rat retina", FEBS Lett, 564, pp.19~23 (2004)

관련 논문AI추천

Triamcinolone Acetonide Prevents Enhancement of Hypoxia-induced Neuronal and Inducible Nitric Oxide Synthases in the Retinas of Rats with Oxygen-induced Retinopathy김성재, 김영희, 유지명, 정인영, 최완성대한안과학회 · Korean Journal of Ophthalmology2012 · 제26권 제6호산소유발망막병증 쥐 모델에서 커큐민의 효과구용리, 김상진, 김영주, 유형곤대한안과학회 · 대한안과학회지2013 · 제54권 제10호Gene Expression Changes in a Rat Model of Oxygen-Induced Retinopathy박종문, 유지명, 정인영, Jun Kyoung Song, Na Eun Lee, Seong Wook Seo, Yeon Jeong Park대한안과학회 · Korean Journal of Ophthalmology2011 · 제25권 제1호용량에 따른 유리체강내 트리암시놀론 주입과 베바시주맙 주입이 안압에 미치는 영향박성배, 박종서, 하성우대한안과학회 · 대한안과학회지2010 · 제51권 제11호망막분지정맥폐쇄의 황반부종과 당뇨황반부종에 무보존제 트리암시놀론 유리체내주사 후 안압상승 비교서영승, 이찬호대한안과학회 · 대한안과학회지2020 · 제61권 제2호분지망막정맥폐쇄에서 베바시주맙군과 저용량 베사시주맙-트리암시놀론 혼합군의 단기 효과 비교강현지, 서진석, 신민호, 정인영대한안과학회 · 대한안과학회지2018 · 제59권 제7호

이 간행물의 다른 논문 (29건)

조절과 눈모음 및 눈모음이상임현택, 백혜정pp. 1719-1726눈물점 협착 환자에서 고주파 수술기구를 이용한 눈물점 성형술의 효과권준기, 이태수, 장민욱, 백세현pp. 1727-1731비특이성안와염 환자에서 적외선 체열 촬영 검사의 결과백지선, 양석우, 류정완, 황호식pp. 1732-1736선천 눈꺼풀처짐 환아에서 눈꺼풀올림근절제 및 이마근걸기 동시수술의 효과김상덕, 최창욱, 김아론pp. 1737-1741레스토Ⓡ 다초점 인공수정체 삽입술 후 잔여굴절이상에 대한 레이저 굴절교정수술 효과김성인, 김숙진, 오재윤, 박규홍, 강석재pp. 1742-1748
원문 보기